Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QMF149 versus salmeterol + fluticasone in COPD
2012-001172-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QMF149 once daily with Salmeterol + fluticasone twice daily (2 arms). Primary endpoint: Trough Forced Expiratory Volume in one second (FEV1). Started Aug 2012; status: completed.
02
Drugs
atectura breezhalersalmeterolfluticasone propionate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-001172-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001172-12.